UNSPSC 51112705: Oxaliplatin

This classification denotes a platinum compound with the molecular formula C8H14N2O4Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04ZR38536J, chemically known as (sp-4-3-(cis))-(1,2-cyclohexanediamine-n,n)(ethanedioato(2-)-o,o)platinum but more generally known as oxaliplatin, which bears US NIH Compound Identifier 77994. European Medicines Agency schedules Oxaliplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09490MIG. The term OXALIPLATIN is an International Non-Proprietary Name.

UNSPSC 51112705 Oxaliplatin, a Commodity code, covers the procurement of this specific chemotherapy pharmaceutical—a platinum-based anticancer drug used in colorectal and ovarian cancer treatment protocols. State and local governments acquire oxaliplatin primarily through pharmacy benefit programs, state Medicaid agencies, and health and human services departments that serve employee health plans and safety-net populations. The recent Texas Health and Human Services Commission RFI signals growing state interest in direct-to-manufacturer contracting models for prescription drugs, moving away from traditional pharmacy benefit manager and group purchasing organization intermediaries to negotiate pricing and manage fulfillment directly.

Texas HHS Commission issued RFI No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to gather vendor capabilities and market intelligence on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks vendor experience with direct contracting for self-insured employers and government health plans, flexibility to negotiate net pricing without rebates, and capacity to support value-based or outcomes-based agreements. No award amount, contract duration, or formal evaluation criteria are specified; the RFI functions as a preliminary market-research tool to inform Texas HHS's future procurement strategy before issuing a formal RFP. This activity reflects a broader state-level shift toward alternative drug-procurement channels and cost-containment strategies, though the source provides limited visibility into activity under the code across other jurisdictions or recent solicitations beyond Texas.